COMPANY PROFILE

Tyrogenex

Explore full profile

Biotechnology company researching and developing treatments for solid tumors

West Palm Beach, United StatesFounded 2006Biotech & Life Sciences

Valuation $50–100M Last recorded · 2014

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Tyrogenex

Tyrogenex operates in the biopharmaceutical industry, focusing on the development and commercialization of biosimilars and screening reagents. The company primarily serves healthcare providers, pharmaceutical companies, and research institutions. Tyrogenex's core business involves creating biosimilars, which are highly similar to already approved biological medicines, to treat conditions such as Wet Age-Related Macular Degeneration and various forms of cancer. These biosimilars offer cost-effective alternatives to original biologics, making advanced treatments more accessible. The company also develops lead compound screening reagents, which are essential tools in drug discovery and development processes.

Tyrogenex generates revenue through the sale of its biosimilars and screening reagents. The company operates in a highly regulated market, adhering to stringent quality and safety standards set by health authorities like the FDA. By focusing on cost-effectiveness and efficacy, Tyrogenex aims to address the growing demand for affordable biologic treatments.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: West Palm Beach, United States
Open positions: None listed
Dealroom signal: 20.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBT✓Debt	Feb 2016	$540K	—	Undisclosed	—
SERIES D✓Equity / VC	Jun 2014	$15M	$60M	Brace Pharma	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Tyrogenex website traffic

Latest recorded traffic for Tyrogenex is 200 monthly website visits, up 0% over the last three months.

Latest monthly visits200 3-month web change0%

Monthly website visitsOct 2017–Jan 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
NHNew Horizon HealthResearches and develops technology for early-stage cancer screening	Hangzhou, China	Operational
SGSinglera GenomicsA developer of 'liquid biopsy' analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA	San Diego, United States	Operational
CDCancerGuide DiagnosticsMolecular diagnostics company developing genomic-based clinical and pharmaceutical cancer tests and services	Durham, United States	Closed
PGPhase GenomicsPhase Genomics' mission is to help scientists make breakthrough discoveries by providing the most complete, accurate, detailed genomes	Seattle, United States	Operational
PIPierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments	St. Louis, United States	Acquired
PEPertheraHope to advanced-stage cancer patients through advanced tumor analysis	McLean, United States	Operational
CICirinaAt Cirina we are pioneering products that detect cancer at its earliest stages and empower you to take action	New York City, United States	Operational